A round of Series C financing led by Tiger Partners and Forbion Capital Partners pulled in $30 million for Exosome Diagnostics. The proceeds will be used for a rapid commercial expansion of the ExoDx Prostate (IntelliScore) test, as well as to commercialize oncological diagnostics, develop tests for other applications, conduct investigations into new technologies and expand the company's companion diagnostics and instrumentation arms.
Funding round pulls in $30M for Exosome Diagnostics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.